Spain's Health Ministry refuses to fund the meningococcal B vaccine

Health Ministry refuses to add the meningococcal B vaccine to the immunisation schedule

A 16-year-old teenager dies in hospital and another, aged 17, remains admitted. Meningococcal meningitis is back in the headlines and, with it, the same uncomfortable question: why is the vaccine covering serogroup B not publicly funded for everyone? The outbreak declared in the UK, with pharmacies running out of stock, has lit the fuse. In Spain, as of this discussion, the Valencian Regional Health Ministry (Conselleria de Sanidad) was investigating the possible meningitis death of a 17-year-old girl at the Hospital de Dénia.

The bacteria is not a bicho. It is transmitted through close, prolonged contact with respiratory secretions: coughing, sneezing, sharing a glass. Without antibiotic treatment, mortality can reach 100% within 24-48 hours; with prompt treatment, it stands at around 10-15%. Some survivors are left with permanent after-effects: deafness, brain damage, fruta.

Which serogroups are circulating and which one is left out of the schedule

Meningococcus is divided into serogroups: A, B, C, W, X, Y. In Spain, B is the most common and the one left out of public funding, on the grounds of its "low incidence" and "protection of limited duration". Serogroups W and Y, which surged in Europe from 2015 onwards, did make it into the schedule once the alarm reached the paperwork.

Some argue that it is not the incidence that is low, but the coverage. Galicia announced it would complete protection with a booster dose at age 12. The Health Ministry rejected the measure. The discrepancy between Spain's autonomous regions is, in itself, the telling fact.

Why cases are concentrated in vaccinated adolescents

One of the most frequently asked questions: why are those affected young people born around 2010, with several meningitis doses already given, rather than adults who grew up without any vaccine? The answer is not settled. What is documented is that the vaccines in the schedule cover specific serogroups, not all of them, and that herd immunity weakens when coverage is partial.

The personal accounts circulating are harrowing. One participant describes having had the disease at 13, a week in a coma in intensive care, a month on a drip, and a 16-year-old roommate who did not make it. Another points to a trigger: a heated argument at home, a fever that same night, a stiff neck the next day. Medicine does not confirm that mechanism, but the pattern recurs in the testimonies.

The British outbreak and the vaccine shortage

The outbreak in the UK, of the W strain, began in Kent and spread through London. It drained vaccine supplies and overwhelmed pharmacies. The strain is more aggressive than usual, but the shortage responds to a familiar mechanism: alarmist news, panic buying, stock-outs. It is not a pandemic. It is panic with logistics.

What the schedule does not cover and what covering it costs

The decision not to fund serogroup B has an obvious economic cost: anyone who wants to protect their children pays out of their own pocket. The full calculation, with doses, boosters and prices per region, produces a range that surprises anyone seeing it for the first time. The question is not whether the vaccine works, but who foots the bill.

The schedule itself provides the closing note: the protection that exists is what someone decided to pay for. What is missing, too.